RCTs, particularly the pivotal RCTs leading to regulatory approval, have been criticized for not reflecting “real-world” DES use.However, individual RCTs are underpowered to assess low frequency endpoints.In most individual RCTs, DES have reduced the rates of TLR and TVR compared to BMS, with no significant differences in death or MI.Research grants from Boston Scientific and Abbott Vascular.Consultant/Speaker: Medtronic Vascular, Abbott Vascular (modest).Past honorarium from Boston Scientific Corporation (modest).BMS Randomized Trials and Registries Ajay J.
